Viracta is a startup based in Israel.
Viracta is a precision oncology company developing therapies for virally associated cancers; its investigational drug Natinostat is designed to induce expression of Epstein–Barr virus (EBV) genes so that, when combined with the antiviral valganciclovir, cancer cells are killed. The approach is being tested in clinical studies for EBV-positive lymphomas and solid tumors.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.